MOBILE AGENDA

 

London, 20 - 21 March 2018

Schedule

Create your personal agenda –check the favourite icon

Mar 2008:55
Conference pass

Chair’s opening remarks

Keynotes
Jeff Myers, CEO, Medicaid Health Plans of America
Mar 2009:00
Conference pass

Keynote opening address

Keynotes
Andrew Dillon, Chief Executive, National Institute for Health and Care Excellence
Mar 2009:40
Conference pass

Keynote panel: Engaging all key stakeholders to improve access and pricing

Keynotes
  • Overview of European and global initiatives and next steps
  • How can we work better for the patient?
  • Working with payers, patients and pharma to generate value
Thomas Mueller, Head of Pharmaceuticals, G-BA
Anne Toni Rodgers, Global Head Operations Payer And Real World Evidence, AstraZeneca
Sachin Kamal-Bahl, Vice President & Head, Global Health & Value Innovation Center , Pfizer
Mar 2011:20
Conference pass

Chair’s remarks

Immuno Therapies and Combination Therapies
Erik Smets, Vice President, Head of Patient Experience and Value, U.C.B. Pharma
Mar 2011:25
Conference pass

Achieving long term accessibility to RWE for key players

Evidence
Peter Speyer, Global Head of Real World Evidence Solutions, Novartis
Mar 2011:25
Conference pass

Ensuring the patients voice in reimbursement for rare diseases

Rare Diseases
Mar 2011:25
Conference pass

Examining pricing models in the Central Nervous System space

Pricing, Market Access & Value
  • Overview of pricing models
  • Challenges for innovative pricing in CNS
  • Potential solutions 
Barbara Jaszewski, VP, Global Pricing & Market Access, H. Lundbeck A/S
Mar 2011:25
Conference pass

Market access and commercial developments for immuno-oncology products

Immuno Therapies and Combination Therapies
  • Rate of IO trial initiation has doubled in the past 12 months with more than 50 new trials now starting each month. And in spite of recent unfavourable trial results, three quarters of the respondents of a beacon intelligence survey predicted this rate of growth will be sustained.
  • Rapid evolution of the IO market requires close coordination and alignment between Key stakeholders
  • How to balance economic pressures, value for patients and the industry 
Mar 2011:25
Conference pass

Role of Big data in prescription registries

Big Data, AI & Digital
Shameer Khader, Director of Bioinformatics, Data Science & Precision Medicine, Philips
Mar 2011:45
Conference pass

Harnessing Real World Evidence to Meet Payer Demands

Evidence
  • Understand the impact of real world evidence (RWE) and real world data (RWD) on clinical trials and commercialisation
  • Discover how emerging technologies can create greater value from your RWD investments
  • Learn best practices for establishing real world value in the eyes of payers and other key stakeholders through case study examples 
Jane Turner, Senior Principal, Real World Evidence, ICON
Mar 2011:45
Conference pass

Evidence generation for optimal price and access in rare diseases: time to think differently?

Rare Diseases
Cheryl Ball, VP, Evidera
Mar 2012:05
Conference pass

Using a Center of Excellence for Clinical Trial and Program Design to support Market Access

Evidence
  • Driving best practices in soliciting input from Countries, Regions and Market Access professionals during clinical trial design phase.
  • Using RWD to identify patient populations with a combination of high event rates and likelihood to respond to a specific intervention to drive best in class clinical outcomes.
  • Using RWD to identify patient characteristics which predict likelihood of having an adverse event 
Mar 2012:05
Conference pass

Are we ready for indication-based pricing?

Pricing, Market Access & Value
Marco Rauland, Global Head Pricing & Payer Excellence, Merck Group
Mar 2012:05
Conference pass

Examining business opportunities for autoimmune diseases

Immuno Therapies and Combination Therapies
Dan Pettitt, Global Head of Immunology Market Access, Johnson & Johnson
Mar 2012:05
Conference pass
Mar 2012:25
Conference pass

ROUNDTABLES

Evidence
Will Dunlop, Head of Market Access, Mundipharma International Limited
Mar 2012:25
Conference pass

ROUNDTABLES

Rare Diseases
Fabrizio Zucca, Director Patient Access DACH, Sobi
Farzana Malik, Vice President Market Access, Vicarius Pharma
Josie Godfrey, Independent, Duchenne U.K.
Mar 2012:25
Conference pass

ROUNDTABLES

Pricing, Market Access & Value
Donato Scolozzi, Member of Spending Review Working Group, Ministry of Health Italy
Ellen Vanhaeren, Advisor, Minister for Social Security and Public Health, Belgian Federal Government
Hassan Bruneo, Associate Director, Alnylam
Neil Mulcock, Vice President Government Affairs and Policy, Gilead Sciences
Bertrand Tardivel, Head of Global Pricing, Takeda Pharmaceuticals International
Bart Vermeulen, Deputy Director Healthcare at Office of the Minister of Social Affairs and Public Health, Belgian Federal Government
Adel Alzahrani, Senior Pharmacist, Saudi Food & Drug Authority
Klaas Postema, Senior Director Market Access & Pricing Generics Europe, Teva
Mar 2012:25
Conference pass

ROUNDTABLES

Immuno Therapies and Combination Therapies
Jenny Ebert, Account Director, Genzyme Sanofi Corp
Michael Schroter, Head of Personalised Reimbursment Models, Global Pricing and Market Access, Roche
Reg Waldeck, Market Access Strategy Leader, Bayer Corp
Diann Potestio, Senior Director, Market Access, West, Genzyme
Jose Diaz, Group Director – JKT Cluster & Intercon Lead - WWHEOR Markets, Bristol Myers Squibb
Mar 2012:25
Conference pass

ROUNDTABLES

Big Data, AI & Digital
Dimitrios Tsourougiannis, Associate Director, EMEA Health Economics & Outcomes Research, Astellas Pharma Europe Ltd
Mar 2014:05
Conference pass
Mar 2014:05
Conference pass

Chair’s remarks

Pricing, Market Access & Value
Katja Berg, Vice President of Operations and Payers Intelligence, Sanofi
Mar 2014:10
Conference pass

USA Perspective: Harnessing RWE to develop a strong market access strategy

Evidence
Mar 2014:10
Conference pass

Market Access Challenges for payers and pharma in rare diseases

Rare Diseases
Mar 2014:10
Conference pass

Integrative care access models: healthcare disrupted from selling pills to selling value

Pricing, Market Access & Value
Hans Peter Frank, Global Head of Integrated Solutions, Vifor Fresenius Medical Care Renal Pharma Ltd
Mar 2014:10
Conference pass

Collaboration between regulators, payers and HTAs in early access

Immuno Therapies and Combination Therapies
Clive Whitcher, Vice President of Global Pricing and Patient Access, Sobi
Mar 2014:10
Conference pass

Relevance of digital for payers; learnings and reflections

Big Data, AI & Digital
  • EU Policy on eHealth and challenges to adoption.
  • Fitting digital into ‘Payer’s value equation’ and understanding the relevance.
  • Opportunities for players; but which players? 
Mar 2014:50
Conference pass

Generating real world evidence from federated data networks in Europe – fit for purpose?

Evidence
  • There are numerous programmes and projects, such as EMIF, the Hospital Network, in IMI and out of it -  an overview
  • What are we trying to achieve in the EU in the lead up to 2020+?
  • What can we learn from our experiences to date, how can we build a genuine network for EU health research? 
Mar 2014:50
Conference pass

Value and Evidence: Challenges and opportunities in rare diseases

Rare Diseases
Omar Dabbous, Head of Quantitative Science Payer Evidence Group, GlaxoSmith Kline
Mar 2014:50
Conference pass

Value modelling from the unmet need to outcomes and revenue

Pricing, Market Access & Value
Peter Vanovertveld, Senior Vice President, Head of Global Pricing & Market Access, Vifor Pharma
Mar 2014:50
Conference pass

Innovative approaches for evidence generation

Immuno Therapies and Combination Therapies
Lara Pippo, Head of Market Access, C.S.L. Behring Spa
Mar 2015:10
Conference pass

Afternoon refreshments

Keynotes

 
Mar 2015:40
Conference pass

Integrating RWE in the clinical development process

Evidence

 
Tony Hebden, Vice President of Health Economics and Outcomes Research, AbbVie
Mar 2015:40
Conference pass

Regulatory landscape and the implications for clinical trial design in rare/ultra-rare diseases

Rare Diseases
  • An update on EU regulatory landscape pertaining to orphan and ultra-orphan diseases
  • Implications for clinical trial design, as well as post-authorization evidence development
  • Implications for HTA in Europe 
Mar 2015:40
Conference pass

Achieving affordable Healthcare Solutions

Pricing, Market Access & Value
  • Focus on preventive care
  • Increased compliance to chronic care
  • Models to demonstrate value
John Alter, Vice President Pricing and Market Access, Pfizer
Mar 2015:40
Conference pass

Reimbursement models across North Africa and the Middle East

Emerging Markets
Mete Saylan, MACS Director, Bayer plc
Mar 2016:00
Conference pass

Sponsor presentation

Evidence

 
Mar 2016:00
Conference pass

Strategic pricing for equitable access in emerging markets

Emerging Markets
Diane Munch, Senior Director of Global Pricing, Pfizer
Sam Taylor, Global Pricing Director, Pfizer Ltd
Mar 2016:20
Conference pass

Examining Data requirements of G-BA

Evidence

 
Friedhelm Leverkus, Director Health Technology Assessment and Outcomes Research, Pfizer
Mar 2016:20
Conference pass

Examining trends of pricing for orphan drugs

Rare Diseases
Fabian Schmidt, Head of Market Access and External Affairs, Orphan Europe
Mar 2016:20
Conference pass

Affordability and sustainability: Risk-share and outcome-based agreements, a future option for innovative drugs for the German market?

Pricing, Market Access & Value
  • The long-term healthcare goals: Patients need access to innovative medicines
  • The reality of rebate contracts: a satisfactory solution for all times?
  • Financial-based risk share contracts: Sharing the risk between the payer and the industry
Mar 2016:20
Conference pass

Biosimilars – savings and sustainability

Immuno Therapies and Combination Therapies
  • To switch or not to switch – to be or not to be?
  • The winner takes all – the problem of the second entrant
  • A lesson on how to throw money out of the window 
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 2016:20
Conference pass

Improving patient access to drugs in South America

Emerging Markets
Marcela Junqueira, Head of Value Demonstration and Access, Shire Farmacêutica Brasil Ltda
Mar 2016:40
Conference pass

Afternoon refreshments

Keynotes

 
Mar 2017:10
Conference pass

Chair’s remarks

Keynotes

 
Wim Colle, President Pulmonary Hypertension Belgium, Flemish Patients Platform vzw
Mar 2017:15
Conference pass

Sponsor speaker

Keynotes

 
Mar 2017:35
Conference pass

Keynote speaker

Keynotes

 
Mar 2017:55
Conference pass

Networking drinks reception

Keynotes

 

Create your personal agenda –check the favourite icon

Mar 2109:00
Conference pass

What is going on in Quebec - Canada about market access?

Keynotes
  • Examining Quebec life sciences strategy: Integration of medicines and technological innovations
  • Achieving cost reduction and improving access to medicines
Luc Boileau, Président-directeur general, Inesss
Mar 2109:40
Conference pass

Keynote Panel: Using evidence to support market access strategies

Keynotes
Thomas Mueller, Head of Pharmaceuticals, G-BA
Mark MacGregor, Associate Medical Director and Clinical Advisor, Scottish Medicines Consortium, NHS National Services Scotland
Mar 2111:00
Conference pass

Chair’s remarks

Evidence
Anne Toni Rodgers, Global Head Operations Payer And Real World Evidence, AstraZeneca
Mar 2111:00
Conference pass

Chair’s remarks

Rare Diseases
Navin Joshi, Head of Pricing & Access Capabilities EMAP, GlaxoSmithKline
Mar 2111:00
Conference pass

Chair’s remarks

Pricing, Market Access & Value
Mar 2111:05
Conference pass

Designing and analysing observational studies for treatment effects using a variety of data sources

Evidence
  • The role of Named Patient- and Early Access Programs in early generation of Real World Evidence
  • How retrospective research can add value in data generation
  • Registries as a data source and company effort
Mar 2111:05
Conference pass

Structural market access challenges in anti-infectives and new funding model ideas

Rare Diseases
Keiko Tone, VP Market Access, Shionogi Limited
Mar 2111:05
Conference pass

Progress on European collaboration for HTA and implications for national settings

Pricing, Market Access & Value
Mar 2111:05
Conference pass

Improving access for patients to new therapies

Advanced Therapies
Darren Walsh, Senior Director - Market Access & Govt. Affairs – EU, Orchard Therapeutics
Mar 2111:25
Conference pass

Unlocking the true value of action on access: enabling patient and market access

Rare Diseases
John Procter, Head of Market Access Europe, QuintilesIMS
Mar 2111:25
Conference pass

National HTA agencies in Europe: is there a need for better collaboration?

Pricing, Market Access & Value
Alexander Grosvenor, Senior Principal of Global Pricing and Market Access, Precision for Value
Nicola Allen, Senior Consultant, Precision for Value
Mar 2111:45
Conference pass

Lessons from Japan: Using RWE for optimal pricing in the presence of co-insurance

Evidence
Joerg Mahlich, Director Health Economics, Janssen Pharmaceutical K.K.
Mar 2111:45
Conference pass

Marketing aspect for pricing

Rare Diseases
Kasia Hein Peters, Vice President and Head of Marketing Dengue Vaccine, Sanofi Pasteur
Mar 2111:45
Conference pass

Latest HTA developments in Europe and Japan

Pricing, Market Access & Value
Adrian Griffin, VP, HTA and Reimbursement Policy, Johnson & Johnson
Mar 2111:45
Conference pass

The challenge of translating value in one-time treatments: Market Access for gene and cell therapies

Advanced Therapies
Mar 2112:05
Conference pass

ROUNDTABLES

Rare Diseases
Ed Pezalla, Former Vice President, National Medical Director for Pharmaceutical Policy and Strategy, Aetna
Mar 2112:05
Conference pass

ROUNDTABLES

Pricing, Market Access & Value
Dawn Torrence Ireland, President and Founder, C.H.E.R.U.B.S.
James Kavanagh, HEOR and Strategic Pricing Manager, AbbVie
Alicia Granados, Head of Global Health Technology Assessment (HTA) OPI GMAx, Sanofi
Ansgar Hebborn, Head of Global H.T.A. and Payment Policy, F Hoffman La Roche Ag
Mar 2112:05
Conference pass

ROUNDTABLES

Immuno Therapies and Combination Therapies
Fulvio Luccini, Patient Access head, Novartis italy
Andrea Mantovani, Director of Country Market Access, Sanofi Pharma and Vaccines
Mar 2114:05
Conference pass

Chair’s remarks

Evidence
Britta Paschen, VP, Head of Global Evidence and Value Development, Merck KGaA
Mar 2114:05
Conference pass

Chair’s remarks

Pricing, Market Access & Value
Jayne Spink, Chief Executive Officer, Genetic Alliance U.K.
Mar 2114:05
Conference pass

Chair’s remarks

Managed Entry Agreements
Giuseppe Rosano, Member of the Cardiovascular Working Party, European Medicines Agency
Mar 2114:10
Conference pass

Improving market access through RWE

Evidence
Anne Marciniak, Affiliate, Brunel University
Mar 2114:10
Conference pass

Using RWE for infectious diseases

Rare Diseases
  • Identifying the unmet needs and opportunities
  • Generating and using evidence to develop solutions
  • Delivering value and positive outcomes for patients
Mar 2114:10
Conference pass

The Patient Voice: Examining the value chain

Pricing, Market Access & Value
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mar 2114:10
Conference pass

Examining the value of managed entry agreements

Managed Entry Agreements
Mar 2114:50
Conference pass

Examining the new AIFA Innovation Criteria

Evidence
Mauro Patroncini, Pipeline Product Strategy Leader, Roche
Mar 2114:50
Conference pass

Developing effective evidence for rare diseases

Rare Diseases
  • Addressing stakeholder perspectives
  • Challenges in developing evidence in the rare disease space
  • How to build an effective value strategy 
Patrick Mollon, Director GHEORE, Shire
Mar 2114:50
Conference pass

Role of HEOR studies in supporting entry agreements

Managed Entry Agreements
Entela Xoxi, Research Fellow, Universita Cattolica Del Sacro Cuore
Mar 2116:00
Conference pass

Future product development and launch by integrating RWE across functions (Clinical Development, Medical, Market Access, Marketing)

Evidence
Sally Lee, Director of Pharmacodepidemiology EMEA / APAC, Celgene
Mar 2116:00
Conference pass

The reimbursement landscape for medicines for rare diseases

Rare Diseases
  • Repurposed medicines – what is a fair price, considering the evidence?
  • Conditional approval and adaptive pathways – what does this mean for reimbursement and post-approval evidence generation?
  • Learnings from MoCA 
Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)
Mar 2116:00
Conference pass

New trends in payer engagement models

Pricing, Market Access & Value
  • Global trends driving need for new ways of stakeholder engagement
  • Archetype of payer engagement models for capability building, research and policy making
  • Learnings from established solutions and exchange of ideas for future collaboration
Mar 2116:00
Conference pass

Using RWE to achieve flexible pricing solutions

Reimbursement
Michael Schroter, Head of Personalised Reimbursment Models, Global Pricing and Market Access, Roche
last published: 19/Oct/17 08:45 GMT